Tofacitinib patent expiration?

Tofacitinib’s patent status isn’t a single date. There are multiple patent families (composition of matter, salts/formulations, methods of use, crystal forms, etc.) and protections differ by country. Because of that, “patent expiration” can vary:

- United States: The core composition-of-matter patent and related patents have expirations that are in the 2020s range, depending on term adjustments and pediatric extensions. Some other patents in the same family may extend protection into the late 2020s in some cases.
- Europe: Apart from individual patents, supplementary protection certificates (SPCs) can push product protection into the mid-2020s in various EU countries.
- Data exclusivity: In major markets, regulatory data protection can delay generic entry even after patents expire (e.g., US data exclusivity is typically 5 years for a new chemical entity; EU has an 8-year data protection period plus additional market exclusivity in some cases).

Because the exact expiry depends on the specific patent family (composition, salt forms, formulations, methods of use) and the country, I can give precise dates if you specify:
- the country/region you care about (US, EU, UK, etc.), and
- which patent type you want (composition of matter, salt/formulation, method of use).

If you want, I can guide you to current expiry data sources (USPTO Patent Center, Google Patents, Espacenet) and outline the relevant patent families for tofacitinib.